Shin Fukudo

List of Publications by Year
in descending order

140 papers	7,685 citations	53660 45 h-index	54797 84 g-index
143 all docs	143 docs citations	143 times ranked	6141 citing authors

#	Article	IF	Citations
1	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 2021, 160, 99-114.e3.	0.6	913
2	Irritable bowel syndrome. Nature Reviews Disease Primers, 2016, 2, 16014.	18.1	674
3	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut, 2017, 66, 1075-1082.	6.1	368
4	Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut, 1998, 42, 845-849.	6.1	344
5	Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterology and Motility, 2009, 22, 512-9, e114-5.	1.6	324
6	Gender, Age, Society, Culture, and the Patientâ€™s Perspective in the Functional Gastrointestinal Disorders. Gastroenterology, 2006, 130, 1435-1446.	0.6	320
7	Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut, 2004, 53, 958-964.	6.1	245
8	Specific brain processing of facial expressions in people with alexithymia: an H215Oâ€PET study. Brain, 2003, 126, 1474-1484.	3.7	198
9	Asian consensus on irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1189-1205.	1.4	141
10	Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits. American Journal of Gastroenterology, 2008, 103, 2550-2561.	0.2	134
11	The alexithymic brain: the neural pathways linking alexithymia to physical disorders. BioPsychoSocial Medicine, 2013, 7, 1.	0.9	125
12	Patients and Nonconsulters with Irritable Bowel Syndrome Reporting a Parental History of Bowel Problems Have More Impaired Psychological Distress. Digestive Diseases and Sciences, 2004, 49, 1046-1053.	1.1	124
13	Evidence-based clinical practice guidelines for irritable bowel syndrome. Journal of Gastroenterology, 2015, 50, 11-30.	2.3	123
14	Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. Journal of Gastroenterology, 2007, 42, 48-51.	2.3	118
15	Brain-Gut Response to Stress and Cholinergic Stimulation in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 1993, 17, 133-141.	1.1	110
16	Correlation between alexithymia and hypersensitivity to visceral stimulation in human. Pain, 2007, 132, 252-263.	2.0	106
17	Gastrointestinal symptoms and disorders in patients with eating disorders. Clinical Journal of Gastroenterology, 2015, 8, 255-263.	0.4	101
18	Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome.. Tohoku Journal of Experimental Medicine, 1987, 151, 373-385.	0.5	99

#	Article	IF	Citations
19	Neural Basis of Impaired Cognitive Flexibility in Patients with Anorexia Nervosa. PLoS ONE, 2013, 8, e61108.	1.1	92
20	Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. Gastroenterology, 2016, 150, 358-366.e8.	0.6	90
21	Altered Cognitive Function of Prefrontal Cortex During Error Feedback in Patients With Irritable Bowel Syndrome, Based on fMRI and Dynamic Causal Modeling. Gastroenterology, 2012, 143, 1188-1198.	0.6	88
22	Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation. Clinical Gastroenterology and Hepatology, 2015, 13, 294-301.e5.	2.4	88
23	Lifestyle and psychological factors related to irritable bowel syndrome in nursing and medical school students. Journal of Gastroenterology, 2011, 46, 1403-1410.	2.3	85
24	Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterology and Motility, 2011, 23, 544-e205.	1.6	80
25	Decreased histamine H1 receptor binding in the brain of depressed patients. European Journal of Neuroscience, 2004, 20, 803-810.	1.2	79
26	Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. NeuroImage, 2009, 47, 946-951.	2.1	78
27	Gender difference in association between polymorphism of serotonin transporter gene regulatory region and anxiety. Journal of Psychosomatic Research, 2006, 60, 91-97.	1.2	76
28	Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. Journal of Gastroenterology, 2021, 56, 193-217.	2.3	73
29	Gene, environment, and brainâ€gut interactions in irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 110-115.	1.4	69
30	Effect of Ramosetron on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea. Clinical Gastroenterology and Hepatology, 2014, 12, 953-959.e4.	2.4	69
31	Stress and visceral pain: Focusing on irritable bowel syndrome. Pain, 2013, 154, S63-S70.	2.0	67
32	Understanding Neurogastroenterology From Neuroimaging Perspective: A Comprehensive Review of Functional and Structural Brain Imaging in Functional Gastrointestinal Disorders. Journal of Neurogastroenterology and Motility, 2018, 24, 512-527.	0.8	64
33	Second Asian Consensus on Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2019, 25, 343-362.	0.8	59
34	Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). BioPsychoSocial Medicine, 2007, 1, 6.	0.9	57
35	Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome. Scientific Reports, 2017, 7, 12425.	1.6	56
36	Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. Journal of Gastroenterology, 2006, 41, 491-494.	2.3	55

#	Article	IF	Citations
37	Corticotropin-Releasing Hormone Receptor 1 Antagonist Blocks Brainâ€“Gut Activation Induced by Colonic Distention in Rats. Gastroenterology, 2005, 129, 1533-1543.	0.6	54
38	Multicultural Aspects in Functional Gastrointestinal Disorders (FGIDs). Gastroenterology, 2016, 150, 1344-1354.e2.	0.6	54
39	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clinical Gastroenterology and Hepatology, 2022, 20, e945-e956.	2.4	52
40	Involvement of the 5-HT₃ receptor in CRH-induced defecation in rats. American Journal of Physiology - Renal Physiology, 1998, 274, G827-G831.	1.6	50
41	Sex differences in brain response to anticipated and experienced visceral pain in healthy subjects. American Journal of Physiology - Renal Physiology, 2013, 304, G687-G699.	1.6	50
42	Effect of Autogenic Training on General Improvement in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial. Applied Psychophysiology Biofeedback, 2010, 35, 189-198.	1.0	49
43	Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. Journal of Gastroenterology, 2002, 37, 145-150.	2.3	48
44	Brain activity during distention of the descending colon in humans. Neurogastroenterology and Motility, 2004, 16, 299-309.	1.6	47
45	Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2007, 19, 471-483.	1.6	47
46	High Prevalence of Irritable Bowel Syndrome in Medical Outpatients in Japan. Journal of Clinical Gastroenterology, 2008, 42, 1010-1016.	1.1	46
47	Corticotropinâ€releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogastroenterology and Motility, 2008, 20, 1147-1156.	1.6	44
48	Increased Brain Histamine H1 Receptor Binding in Patients with Anorexia Nervosa. Biological Psychiatry, 2009, 65, 329-335.	0.7	44
49	Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan. BioPsychoSocial Medicine, 2016, 10, 19.	0.9	44
50	Food-deprived activity stress decreased the activity of the histaminergic neuron system in rats. Brain Research, 2001, 891, 32-41.	1.1	41
51	Injection of corticotropinâ€releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats. Neurogastroenterology and Motility, 2015, 27, 30-39.	1.6	40
52	Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia. Journal of Neurogastroenterology and Motility, 2015, 21, 537-544.	0.8	39
53	Autonomic dysregulation in IBS. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 569-571.	8.2	37
54	Development of a Japanese version of the Somatic Symptom Scale-8: Psychometric validity and internal consistency. General Hospital Psychiatry, 2017, 45, 7-11.	1.2	37

#	Article	IF	Citations
55	Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2011, 23, 754-e332.	1.6	36
56	Common and distinct neural representations of aversive somatic and visceral stimulation in healthy individuals. Nature Communications, 2020, 11, 5939.	5.8	33
57	Gastrointestinal specific anxiety in irritable bowel syndrome: validation of the Japanese version of the visceral sensitivity index for university students. BioPsychoSocial Medicine, 2014, 8, 10.	0.9	32
58	Epidemiology of irritable bowel syndrome. Annals of Gastroenterology, 2015, 28, 158-159.	0.4	32
59	Differential Activation in Amygdala and Plasma Noradrenaline during Colorectal Distention by Administration of Corticotropin-Releasing Hormone between Healthy Individuals and Patients with Irritable Bowel Syndrome. PLoS ONE, 2016, 11, e0157347.	1.1	30
60	Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 603-613.	3.7	29
61	Highâ€dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, doubleâ€blind, placeboâ€controlled study with a longâ€term openâ€label extension study in Japan. Neurogastroenterology and Motility, 2019, 31, e13487.	1.6	27
62	Colorectal distention induces hippocampal noradrenaline release in rats: an in vivo microdialysis study. Brain Research, 2002, 947, 146-149.	1.1	26
63	Neural Substrates of Decision Making as Measured With the Iowa Gambling Task in Men With Alexithymia. Psychosomatic Medicine, 2011, 73, 588-597.	1.3	26
64	Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, doubleâ€blind, placeboâ€controlled study. Neurogastroenterology and Motility, 2018, 30, e13275.	1.6	26
65	Effects of personality traits on the manifestations of irritable bowel syndrome. BioPsychoSocial Medicine, 2012, 6, 20.	0.9	24
66	Lewy body constipation. Journal of the Anus, Rectum and Colon, 2019, 3, 10-17.	0.4	24
67	Corticotropin-Releasing Hormone Receptor 1 Gene Variants in Irritable Bowel Syndrome. PLoS ONE, 2012, 7, e42450.	1.1	23
68	Association Between Alexithymia and Functional Gastrointestinal Disorders. Frontiers in Psychology, 2018, 9, 599.	1.1	22
69	Influence of Uncertain Anticipation on Brain Responses to Aversive Rectal Distension in Patients With Irritable Bowel Syndrome. Psychosomatic Medicine, 2017, 79, 988-999.	1.3	21
70	A randomized controlled and longâ€term linaclotide study of irritable bowel syndrome with constipation patients in Japan. Neurogastroenterology and Motility, 2018, 30, e13444.	1.6	21
71	Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 2021, 19, 538-546.e8.	2.4	21
72	Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome. PLoS ONE, 2016, 11, e0147817.	1.1	21

#	Article	IF	Citations
73	Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. Journal of Gastroenterology, 2016, 51, 874-882.	2.3	20
74	Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study. Journal of Gastroenterology, 2019, 54, 530-540.	2.3	20
75	Can modulating corticotropin releasing hormone receptors alter visceral sensitivity?. Gut, 2006, 55, 146-148.	6.1	19
76	Role of histaminergic neurons in hypnotic modulation of brain processing of visceral perception. Neurogastroenterology and Motility, 2007, 19, 831-838.	1.6	19
77	Impact of symptoms by gender and age in Japanese subjects with irritable bowel syndrome with constipation (IBS-C): a large population-based internet survey. BioPsychoSocial Medicine, 2018, 12, 12.	0.9	19
78	Optimal dose of ramosetron in female patients with irritableÂbowel syndrome with diarrhea: A randomized, placeboâ€controlled phase II study. Neurogastroenterology and Motility, 2017, 29, e13023.	1.6	17
79	Resting state functional connectivity of the pain matrix and default mode network in irritable bowel syndrome: a graph theoretical analysis. Scientific Reports, 2020, 10, 11015.	1.6	17
80	Management and Pathophysiology of Functional Gastrointestinal Disorders. Digestion, 2012, 85, 85-89.	1.2	16
81	Effect of 5â€hydroxytryptamine receptor 4 agonist mosapride on human gastric accommodation. Neurogastroenterology and Motility, 2015, 27, 1303-1309.	1.6	16
82	Survey of Clinical Practice for Irritable Bowel Syndrome in East Asian Countries. Digestion, 2015, 91, 99-109.	1.2	16
83	Abnormal visceral perception in patients with functional dyspepsia: use of cerebral potentials evoked by electrical stimulation of the oesophagus. Neurogastroenterology and Motility, 2000, 12, 87-94.	1.6	15
84	Doseâ€finding study of linaclotide in Japanese patients with chronic constipation: A phase <scp>II</scp> randomized, doubleâ€blind, and placeboâ€controlled study. Neurogastroenterology and Motility, 2018, 30, e13442.	1.6	15
85	Insula Activity to Visceral Stimulation and Endocrine Stress Responses as Associated With Alexithymia in Patients With Irritable Bowel Syndrome. Psychosomatic Medicine, 2020, 82, 29-38.	1.3	15
86	Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterology and Motility, 2005, 17, 705-713.	1.6	14
87	A neurological approach to biopsychosocial medicine: Lessons from irritable bowel syndrome. BioPsychoSocial Medicine, 2011, 5, 1.	0.9	13
88	Effects of Preceding Stimulation on Brain Activation in Response to Colonic Distention in Humans. Psychosomatic Medicine, 2013, 75, 453-462.	1.3	13
89	Parasympathetic activity correlates with subjective and brain responses to rectal distension in healthy subjects but not in non-constipated patients with irritable bowel syndrome. Scientific Reports, 2019, 9, 7358.	1.6	13
90	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study. PLoS ONE, 2020, 15, e0234089.	1.1	13

#	Article	IF	Citations
91	Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey. BioPsychoSocial Medicine, 2018, 12, 18.	0.9	12
92	Clinical Usefulness of Endoscopy, Barium Fluoroscopy, and Chest Computed Tomography for the Correct Diagnosis of Achalasia. Internal Medicine, 2020, 59, 323-328.	0.3	11
93	Associations between Single-Nucleotide Polymorphisms in Corticotropin-Releasing Hormone-Related Genes and Irritable Bowel Syndrome. PLoS ONE, 2016, 11, e0149322.	1.1	11
94	Differential responding of autonomic function to histamine H1 antagonism in irritable bowel syndrome. Neurogastroenterology and Motility, 2010, 22, 1284-e335.	1.6	10
95	Maladjustment to Academic Life and Employment Anxiety in University Students with Irritable Bowel Syndrome. PLoS ONE, 2015, 10, e0129345.	1.1	10
96	Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation. Alimentary Pharmacology and Therapeutics, 2020, 52, 430-441.	1.9	10
97	Imaging Brain Mechanisms of Functional Somatic Syndromes: Potential as a Biomarker?. Tohoku Journal of Experimental Medicine, 2020, 250, 137-152.	0.5	9
98	Serotonin Transporter Gene Polymorphism Modulates Activity and Connectivity within an Emotional Arousal Network of Healthy Men during an Aversive Visceral Stimulus. PLoS ONE, 2015, 10, e0123183.	1.1	9
99	A Questionnaire-Based Survey on the Impact of the COVID-19 Pandemic on Gastrointestinal Endoscopy in Asia. Digestion, 2022, 103, 7-21.	1.2	9
100	Relationship between sympathoadrenal and pituitary-adrenal response during colorectal distention in the presence of corticotropin-releasing hormone in patients with irritable bowel syndrome and healthy controls. PLoS ONE, 2018, 13, e0199698.	1.1	8
101	Cognitive behavioral therapy with interoceptive exposure and complementary video materials for irritable bowel syndrome (IBS): protocol for a multicenter randomized controlled trial in Japan. BioPsychoSocial Medicine, 2019, 13, 14.	0.9	7
102	Oxytocin antagonist induced visceral pain and corticotropin-releasing hormone neuronal activation in the central nucleus of the amygdala during colorectal distention in mice. Neuroscience Research, 2021, 168, 41-53.	1.0	7
103	Enhanced Auditory Brainstem Response and Parental Bonding Style in Children with Gastrointestinal Symptoms. PLoS ONE, 2012, 7, e32913.	1.1	7
104	Effect of repetitive transcranial magnetic stimulation on rectal function and emotion in humans. Journal of Gastroenterology, 2011, 46, 1071-1080.	2.3	6
105	Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea. BioPsychoSocial Medicine, 2017, 11, 8.	0.9	6
106	Effect of attention bias modification on brain function and anxiety in patients with irritable bowel syndrome: A preliminary electroencephalogram and psychoâ€behavioral study. Neurogastroenterology and Motility, 2017, 29, e13131.	1.6	6
107	Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. BioPsychoSocial Medicine, 2017, 11, 7.	0.9	6
108	Effect of attention bias modification on eventâ€related potentials in patients with irritable bowel syndrome: A preliminary brain function and psychoâ€behavioral study. Neurogastroenterology and Motility, 2018, 30, e13402.	1.6	6

#	Article	IF	Citations
109	Biopsychosocial medicine research trends: connecting clinical medicine, psychology, and public health. BioPsychoSocial Medicine, 2020, 14, 30.	0.9	6
110	Modification of rectal function and emotion by repetitive transcranial magnetic stimulation in humans. Neuroscience Research, 2021, 168, 54-63.	1.0	6
111	Dai-Kenchu-To, a Herbal Medicine, Attenuates Colorectal Distention-induced Visceromotor Responses in Rats. Journal of Neurogastroenterology and Motility, 2016, 22, 686-693.	0.8	5
112	Eating Disorder Neuroimaging Initiative (EDNI): a multicentre prospective cohort study protocol for elucidating the neural effects of cognitiveâ€“behavioural therapy for eating disorders. BMJ Open, 2021, 11, e042685.	0.8	5
113	Effectiveness of enhanced cognitive behavior therapy for bulimia nervosa in Japan: a randomized controlled trial protocol. BioPsychoSocial Medicine, 2020, 14, 2.	0.9	4
114	Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study. Frontiers in Psychiatry, 2021, 12, 673939.	1.3	3
115	Histamine Neuroimaging in Stress-Related Disorders. Current Topics in Behavioral Neurosciences, 2021, , 113-129.	0.8	3
116	Exaggerated visceresensory evokad potentials in irritable bowel syndrome. Gastroenterology, 2001, 120, A750.	0.6	2
117	Mo1281 Optimal Dose of Ramosetron in Female Patients With Irritable Bowel Syndrome With Diarrhea: A Randomized, Placebo-Controlled Phase II Trial. Gastroenterology, 2015, 148, S-659.	0.6	2
118	Linaclotide is Effective and Safe for Patients with Irritable Bowel Syndrome with Constipation in Japan: A Phase III Randomized, Double-Blind, and Placebo-Controlled and Long-Term Extension Study. Gastroenterology, 2017, 152, S714.	0.6	2
119	Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation. Gastroenterology, 2019, 157, 898-899.	0.6	2
120	Concordant pattern of the HPA axis response to visceral stimulation and CRH administration. Neuroscience Research, 2021, 168, 32-40.	1.0	2
121	Exaggerated visceresensory evokad potentials in irritable bowel syndrome. Gastroenterology, 2001, 120, A750-A750.	0.6	2
122	M1788 Effect of Therapeutic Guideline On Irritable Bowel Syndrome: A Randomized Controlled Trial. Gastroenterology, 2008, 134, A-419.	0.6	1
123	Evaluation of Kampo medicine in the clinical practice guideline for irritable bowel syndrome. Journal of Gastroenterology, 2015, 50, 817-818.	2.3	1
124	Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress. Clinical Journal of Gastroenterology, 2015, 8, 275-279.	0.4	1
125	Randomized, doubleâ€blind, placeboâ€controlled study vs data in the daily practice using linaclotide in patients with irritable bowel syndrome with constipation. Neurogastroenterology and Motility, 2018, 30, e13363.	1.6	1
126	106 â€“ Altered Gender Difference in Brain Histamine H1 Receptor Binding in Patients with Irritable Bowel Syndrome: A Positron Emission Tomography Study. Gastroenterology, 2019, 156, S-26-S-27.	0.6	1

#	Article	IF	Citations
127	Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation. Journal of Neurogastroenterology and Motility, 2019, 25, 332-333.	0.8	1
128	OC-067â€…Phenotyping visceral pain in humans using brain imaging. Gut, 2010, 59, A28.1-A28.	6.1	0
129	Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 1379.	2.4	0
130	VII. How to Treat Chronic Constipation with Intestinal Secretagogues or Inhibitor of Ileal Bile Acid Transporter. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 46-54.	0.0	0
131	Editorial: minesapride for irritable bowel syndrome with constipationâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 715-716.	1.9	0
132	Role of Brain-Gut Axis in Irritable Bowel Syndrome. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY71-2.	0.0	0
133	Rehabilitation Medicine for Abnormal Visceral Sensitivity in Irritable Bowel Syndromeï¼ˆIBSï¼‰. The Japanese Journal of Rehabilitation Medicine, 2021, 58, 1383-1390.	0.0	0
134	Title is missing!. , 2020, 15, e0234089.		0
135	Title is missing!. , 2020, 15, e0234089.		0
136	Title is missing!. , 2020, 15, e0234089.		0
137	Title is missing!. , 2020, 15, e0234089.		0
138	Title is missing!. , 2020, 15, e0234089.		0
139	Title is missing!. , 2020, 15, e0234089.		0
140	Letter: placebo runâ€in for IBS clinical trials â€•is it useful? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1239-1240.	1.9	0